| Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011 | 9394 | 2011 |
| Final version of 2009 AJCC melanoma staging and classification CM Balch, JE Gershenwald, S Soong, JF Thompson, MB Atkins, DR Byrd, ... Journal of clinical oncology 27 (36), 6199-6206, 2009 | 5700 | 2009 |
| Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq I Tirosh, B Izar, SM Prakadan, MH Wadsworth, D Treacy, JJ Trombetta, ... Science 352 (6282), 189-196, 2016 | 4396 | 2016 |
| Inhibition of mutated, activated BRAF in metastatic melanoma KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, ... New England Journal of Medicine 363 (9), 809-819, 2010 | 4363 | 2010 |
| Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations KT Flaherty, JR Infante, A Daud, R Gonzalez, RF Kefford, J Sosman, ... New England Journal of Medicine 367 (18), 1694-1703, 2012 | 3227 | 2012 |
| Improved overall survival in melanoma with combined dabrafenib and trametinib C Robert, B Karaszewska, J Schachter, P Rutkowski, A Mackiewicz, ... New England Journal of Medicine 372 (1), 30-39, 2015 | 3063 | 2015 |
| Genomic classification of cutaneous melanoma R Akbani, KC Akdemir, B áArman Aksoy, M Albert, A Ally, SB Amin, ... Cell 161 (7), 1681-1696, 2015 | 2893 | 2015 |
| Improved survival with MEK inhibition in BRAF-mutated melanoma KT Flaherty, C Robert, P Hersey, P Nathan, C Garbe, M Milhem, ... New England Journal of Medicine 367 (2), 107-114, 2012 | 2681 | 2012 |
| Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ... New England Journal of Medicine 366 (8), 707-714, 2012 | 2642 | 2012 |
| Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual JE Gershenwald, RA Scolyer, KR Hess, VK Sondak, GV Long, MI Ross, ... CA: a cancer journal for clinicians 67 (6), 472-492, 2017 | 2469* | 2017 |
| Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ... New England Journal of Medicine 371 (20), 1877-1888, 2014 | 2107 | 2014 |
| Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ... Nature 467 (7315), 596-599, 2010 | 2102 | 2010 |
| Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion R Straussman, T Morikawa, K Shee, M Barzily-Rokni, ZR Qian, J Du, ... Nature 487 (7408), 500-504, 2012 | 2015 | 2012 |
| COT drives resistance to RAF inhibition through MAP kinase pathway reactivation CM Johannessen, JS Boehm, SY Kim, SR Thomas, L Wardwell, ... Nature 468 (7326), 968-972, 2010 | 1765 | 2010 |
| RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E) PI Poulikakos, Y Persaud, M Janakiraman, X Kong, C Ng, G Moriceau, ... Nature 480 (7377), 387-390, 2011 | 1692 | 2011 |
| Defining T cell states associated with response to checkpoint immunotherapy in melanoma M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, ... Cell 175 (4), 998-1013. e20, 2018 | 1655 | 2018 |
| Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ... The Lancet 386 (9992), 444-451, 2015 | 1617 | 2015 |
| Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine LT Geller, M Barzily-Rokni, T Danino, OH Jonas, N Shental, D Nejman, ... Science 357 (6356), 1156-1160, 2017 | 1554 | 2017 |
| Mechanisms of resistance to immune checkpoint inhibitors RW Jenkins, DA Barbie, KT Flaherty British journal of cancer 118 (1), 9-16, 2018 | 1379 | 2018 |
| Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma C Robert, JJ Grob, D Stroyakovskiy, B Karaszewska, A Hauschild, ... New England Journal of Medicine 381 (7), 626-636, 2019 | 1337 | 2019 |
